PepGen (PEPG) Cash from Operations (2021 - 2026)
PepGen (PEPG) posted Cash from Operations of 18426000.0 for Q1 2026, down 16.29% sequentially from 15845000.0 in Q4 2025, and up 19.64% YoY from 15400895.97 in Q1 2025.
Powered by 
Analysis
PepGen (PEPG) Cash from Operations (2021 - 2026) Analysis & Trends
PepGen has reported Cash from Operations for 6 years, with the latest figure at 18426000.0 in Q1 2026.
- Quarterly Cash from Operations rose 19.64% year-over-year to 18426000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 77131000.0 (up 6.81% YoY) and the FY2025 annual result came in at 81635000.0, up 0.89% from the prior year.
- Cash from Operations fell to 18426000.0 in Q1 2026 per PEPG's latest filing, from 15845000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 12272000.0 in Q1 2022 and troughed at 24012000.0 in Q3 2024.
- A 5-year average of 18276176.47 and a median of 18426000.0 in 2026 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations sank 333.64% in 2022, then gained 20.43% in 2023.
- Over 5 years, Cash from Operations stood at 13387000.0 in 2022, then slumped by 45.1% to 19424000.0 in 2023, then dropped by 0.26% to 19475000.0 in 2024, then climbed by 18.64% to 15845000.0 in 2025, then declined by 16.29% to 18426000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 18426000.0, 15845000.0, and 19259000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | -15.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.81 Mn |
| Mar 31, 2026 | -18.43 Mn |
| Dec 31, 2025 | -15.85 Mn |
| Sep 30, 2025 | -19.26 Mn |
| Jun 30, 2025 | -23.60 Mn |
| Mar 31, 2025 | -22.93 Mn |
| Dec 31, 2024 | -19.48 Mn |
| Sep 30, 2024 | -24.01 Mn |
| Jun 30, 2024 | -16.35 Mn |
| Mar 31, 2024 | -22.53 Mn |
| Dec 31, 2023 | -19.42 Mn |
| Sep 30, 2023 | -16.68 Mn |
| Jun 30, 2023 | -17.47 Mn |
| Mar 31, 2023 | -15.42 Mn |
| Dec 31, 2022 | -13.39 Mn |
| Sep 30, 2022 | -20.97 Mn |
| Jun 30, 2022 | -12.64 Mn |
| Mar 31, 2022 | -12.27 Mn |
| Dec 31, 2021 | -5.99 Mn |
| Sep 30, 2021 | -7.65 Mn |